Watch the video presentation at The Legacy Continues Gala on February 18, 2023.
What is PRECEDE?
The Pancreatic Cancer Early Detection (PRECEDE) Consortium is an international, multi-institutional collaborative group of experts to increase survival for pancreatic cancer patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. PRECEDE’s mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10% to 50% within the next 10 years. With 48 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking.